The amyloid-β (Aβ) cascade hypothesis of Alzheimer disease (AD) holds that brain accumulation of Aβ initiates the disease process. Accordingly, drug research has targeted Aβ production, clearance, and deposition as therapeutic strategies. Unfortunately, candidate drugs have failed to show clinical benefit in established, early, or prodromal disease, or in those with high AD risk. Currently, monoclonal antibodies specifically directed against the most neurotoxic Aβ forms are undergoing large-scale trials to confirm initially encouraging results. However, recent findings on the normal physiology of Aβ suggest that accumulation may be compensatory rather than the pathological initiator. If this is true, alternative strategies will be needed to defeat this devastating disease.
The amyloid-β (Aβ) cascade hypothesis of Alzheimer disease (AD) holds that brain accumulation of Aβ initiates the disease process. Accordingly, drug research has targeted Aβ production, clearance, and deposition as therapeutic strategies. Unfortunately, candidate drugs have failed to show clinical benefit in established, early, or prodromal disease, or in those with high AD risk. Currently, monoclonal antibodies specifically directed against the most neurotoxic Aβ forms are undergoing large-scale trials to confirm initially encouraging results. However, recent findings on the normal physiology of Aβ suggest that accumulation may be compensatory rather than the pathological initiator. If this is true, alternative strategies will be needed to defeat this devastating disease. ANN NEUROL 2019; 85:303-315 A lzheimer disease (AD) is clinically characterized by significant and progressive cognitive and behavioral impairment, following a long prodrome. Current therapies for AD are symptomatic and do not affect disease progression. Despite progress in understanding the pathophysiology and numerous large-scale studies of new drugs, none has been approved in the past 15 years. 1 ). However, the real problem is that the effect size detected with traditional scales has limited clinical relevance, as the large EXPEDITION-3 solanezumab study indicated. 5 In this study, due to the large sample size (2,129 patients) the mean Mini-Mental State Examination (MMSE) change at week 80 in the solanezumab group was significantly lower than that of the placebo group, but the adjusted difference between the two groups was just 0.49 points, in a cognitive scale that ranges from 0 to 30, with a mean baseline value of 23 points. This difference represents a 13% lowering of the rate of cognitive decline-an effect that, although statistically significant, has limited clinical relevance. For reference, the donepezil-placebo difference in MMSE after 24 weeks of treatment is 1.36 points. 6 We believe that selection of the wrong biological target could be the main reason for the ongoing failure. Because the majority of recent candidates targeted the accumulation of amyloid-β (Aβ) peptide, the present review article will focus on anti-Aβ immunotherapeutic agents, specifically anti-Aβ monoclonal antibodies.
Aβ Cascade Hypothesis of AD
The Aβ peptide is generated by metabolism of amyloid precursor protein (APP). APP may be cleaved by an extraneuronal protease called α-secretase, producing a soluble extracellular fragment, sAPPα. Alternatively, APP is cleaved by β-secretase (or β-site APP cleaving enzyme 1 [BACE1]) generating a soluble extracellular fragment (sAPPβ) and a cell-membrane-bound fragment (C99). C99 is cleaved intracellularly by γ-secretase, releasing amyloid intracellular domain and Aβ. Aβ may have different lengths, the most abundant being of 40 amino acids (Aβ ) and the less soluble 42 amino acid form (Aβ ). Aβ aggregates to form oligomers, protofibrils, fibrils, and plaques, representing one of the hallmarks of AD pathology (Fig 1) .
In the AD brain, Aβ-deposition generally follows a distinct sequence in which the regions are hierarchically involved. Initially, Aβ deposits are found exclusively in the neocortex. In a second phase, allocortical brain regions, then diencephalic nuclei, the striatum, and the cholinergic nuclei of the basal forebrain also exhibit Aβ deposits. Several brainstem nuclei become additionally involved as deposition progresses. Finally, cerebellar Aβ deposition becomes apparent. 7 This regional progressive pattern of amyloid deposition has been confirmed in large in vivo amyloid-positron emission tomography (PET) brain imaging studies. 8 Intracellular deposits of hyperphosphorylated tau protein (neurofibrillary tangles) lead to progressive cytoskeletal changes and axonal transport disruption (see Fig 1) . Aβ accumulation as the pathogenic basis of AD was proposed in the early 1990s. 9, 10 The amyloid cascade hypothesis states that brain Aβ deposition drives tau phosphorylation, tangle formation, synaptic loss, neuronal death, and cognitive impairment. This hypothesis was strongly supported by the discovery that the relatively rare early onset familial AD is caused by autosomal-dominant mutations in presenilin-1 (PSEN1), presenilin-1 (PSEN2), or APP genes. These alter Aβ production, increasing the Aβ 1-42 /Aβ 1-40 ratio and favoring Aβ aggregation and deposition. In 2012, a gene mutation encoding for APP (A673T) was discovered to protect against AD and cognitive decline in normal elderly subjects, further strengthening the theory.
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In late onset sporadic AD, accumulation is believed to be due to defective brain clearance of Aβ 12 and increased BACE activity. 13 Aβ accumulation has also been linked to the strongest genetic risk factor for late onset sporadic AD, apolipoprotein E (APOE), one allele of which (APOE ε4) is consistently linked to abnormal Aβ aggregation, is a predictor of Aβ accumulation in normal older subjects, and increases AD risk by up to 15 times. 14, 15 However, APOE isoforms also have distinct Aβ-independent neural functions that may influence AD risk and age at onset. 14 In man, amyloid pathology can be measured directly by PET or indirectly by Aβ 1-42 levels in cerebrospinal fluid (CSF), which are believed to reflect central nervous system Aβ aggregation. In AD, changes in Aβ concentrations appear in the CSF, followed in sequence by brain Aβ accumulation, increases in CSF tau, hippocampal and gray matter volume losses, decreased glucose metabolism, memory impairment, and dementia. 16 However, postmortem studies indicate that cognitively normal older subjects can have extensive amyloid pathology, 17 with up to 44% having abnormal Aβ deposition by 90 years of age. 18 Prevalence of amyloid pathology increases with age, and subjects with amyloid pathology at baseline generally show more rapid cognitive decline than those without it. 19 Aβ deposition is calculated to precede symptomatic AD by approximately 15 to 20 years. 18, 20 Current AD development models are based mostly on cross-sectional studies in people without dementia who have brain Aβ deposits, but these models are far from accurate. Recently, longitudinal studies in carriers of autosomal-dominant AD mutations have shown unexpectedly variable trajectories for hippocampal atrophy and glucose hypometabolism. 21 In addition, although Aβ accumulation generally precedes tau changes, the exact mechanistic crosstalk between them remains unclear. 22 These findings have stimulated refinement of research classification schemes for disease staging, categories of Aβ and tau pathology, and neuronal injury. 23 
Evolution of the Amyloid Cascade Hypothesis
The amyloid cascade hypothesis has evolved in the past 15 years. 24 Because fibrillar Aβ aggregates correlate poorly with AD severity 25 and plaque removal with immunotherapy does not produce cognitive benefit, 26 researchers have targeted soluble small Aβ aggregates in both AD patients 27 and mouse AD models. 28 The current hypothesis suggests that Aβ neurotoxicity is mediated by soluble oligomers rather than insoluble aggregates; however, the type and the size of oligomers responsible is uncertain. In addition, their dynamic nature renders their measurement in biological samples challenging. 29 Some work indicates the vast majority of soluble Aβ aggregates in the AD brain are large, minimally toxic oligomers, whereas scarcer soluble dimers are much more toxic. 30 Conversely, other work indicates that the large oligomer Aβ*56 induces specific changes in neuronal signaling leading to tau phosphorylation and aggregation, whereas dimers and trimers do not. 31 
Fifteen Years of Clinical Failure with Anti-Aβ Drugs
Numerous drugs either decreasing Aβ production, increasing its clearance, or inhibiting Aβ aggregate formation have failed to improve cognitive outcomes in trials, despite reducing brain Aβ (Table 1) . Supporters of the Aβ hypothesis argue that several of these agents had inadequate preclinical data, poor brain penetration, little biomarker impact, and/or low therapeutic indexes. They also note that such trials enrolled many patients with clinical late-mild and moderate AD, usually without baseline evidence of brain Aβ deposition, and that up to~25% of subjects were subsequently proven Aβ negative, that is, did not have AD. 24, 33 Many of these points are countered by recent BACE inhibitor trials. Development of 4 BACE inhibitors (verubecestat, atabecestat, lanabecestat, and LY3202626) was discontinued because of major clinical setbacks in placebo-controlled trials involving either patients with mild-to-moderate or prodromal AD, or normal subjects at risk of AD. The foremost case is verubecestat, a potent BACE inhibitor able to suppress human CSF Aβ secretion by up to 94%, which worsened cognition and behavior in a 2-year, double-blind, placebo-controlled trial in 1,454 prodromal AD subjects with positive amyloid PET scan at baseline (APECS study). 34 On the primary outcome measure, the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the highest-dose groups (40 mg/day) scored significantly worse than placebo-treated subjects at nearly every time point from 13 to 104 weeks. Participants taking verubecestat also scored worse on the ADCS-Activities of Daily Living functionality scale, this deficit appearing later than the cognitive one, at week 39. Both verubecestat treatment groups (12 and 40 mg/day) progressed to dementia faster than controls, at a rate of 25% per year instead of 20%. Participants on drug also had more anxiety, depression, and disturbed sleep than those on placebo. 34 Verubecestat caused a rapid reduction in brain and hippocampal volume that became significant at week 13, 35 a time coincident with cognitive worsening. Detrimental effects on cognition and mortality in prodromal and established AD patients have also been observed in clinical trials with other anti-Aβ drugs, including semagacestat 36 and avagacestat 37, 38 (both γ-secretase inhibitors), tarenflurbil 39 (a γ-secretase modulator), CAD106 40 (an active anti-Aβ immunotherapy), AD02 41 (another Aβ antigen), and scyllo-inositol 42 (an Aβ aggregation inhibitor).
In reflection of the modified amyloid cascade hypothesis, recent efforts have focused on drugs known to be active against soluble oligomer species. [43] [44] [45] [46] [47] Unfortunately, even The list is ordered by the year of publication of the main results of the studies. Aβ = amyloid-β; AD = Alzheimer disease; LOE = lack of efficacy; MAb = monoclonal antibody; MCI = mild cognitive impairment; PAb = polyclonal antibody; TOX = toxicity.
these more selective anti-Aβ drugs have not yet shown clinical efficacy in AD patients (see Table 1 ). Two antibodies (aducanumab and BAN2401) selective for small aggregate Aβ species (oligomers, protofibrils) have offered promising data in mild or prodromal AD, but these early results have been questioned because of potential study design biases, and larger, confirmatory trials are needed. We now briefly review some of these anti-Aβ monoclonal antibodies, the class of anti-Aβ treatments that is currently being subjected to the most extensive research in AD clinical studies. As mentioned above, numerous examples of other classes of anti-Aβ treatments have failed in the past 15 years. BACE inhibitors have recently suffered a series of clinical setbacks in mild-tomoderate and prodromal AD, 48 although a couple of drugs are still in phase III clinical development (elenbecestat and CNP520). 49 Several anti-tau antibodies have reached phase II clinical development. 50 Pharmacological approaches targeting alternative biological targets are also being actively pursued. 51 There are 3 main hypotheses for the mechanism of anti-Aβ antibodies (Fig 2) . The first involves direct action against the Aβ plaques, fibrils, protofibrils, or oligomers, where antibody binding destabilizes the different aggregate species. The second involves the action of microglia, which leads to the phagocytosis of Aβ mediated by Fc receptors. Lastly, there is the peripheral sink mechanism hypothesis, in which the antibody binds to and removes Aβ present in the plasma, generating a net efflux of Aβ from the brain to the plasma. 
Aβ Immunotherapy
The first anti-Aβ immunotherapy candidate (designed to elicit an immunological response against Aβ) was AN-1792, a preaggregated Aβ with an immunological adjuvant (QS21). This cleared most of the Aβ deposits in the brain of AD patients but without cognitive or clinical benefit. 52 Additionally, AN-1792 elicited an immunological response in about 6% of patients producing serious brain inflammation resembling meningoencephalitis. 52 Other safer Aβ antigens and adjuvants were later developed, but these also failed to produce clinical benefits (see Table 1 ); only CAD106 remains in development. Several passive anti-Aβ monoclonal antibodies have been found clinically ineffective (see Table 1 ). Some (solanezumab, gantenerumab, crenezumab, aducanumab) are now being developed in subjects with early AD and prodromal familial AD, and asymptomatic subjects at high risk of AD, and warrant closer review (Table 2) . Solanezumab Solanezumab (Eli Lilly) is in phase III development for subjects at risk of developing AD. Studies in transgenic mice and humans suggest it recognizes soluble monomeric Aβ and also Aβ plaques. 53 Solanezumab is one of the few anti-Aβ antibodies shown to improve cognitive deficits in some transgenic mouse models of AD, 54 although not in all.
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A double-blind, placebo-controlled phase II study in 52 mild-to-moderate AD patients evaluated different 12-week dose regimens of solanezumab. The drug was generally well tolerated. Total Aβ 1-40 and Aβ 1-42 levels in plasma and CSF increased in a dose-dependent manner, but there were no significant changes in cognitive scores. 56 Two 80-week, double-blind, placebo-controlled phase III studies (EXPEDITION-1 and EXPEDITION-2) in 2,052 mild-to-moderate AD patients failed to show cognitive or functional efficacy. 57 Subgroup analysis of EXPEDI-TION-1, but not EXPEDITION-2, showed that solanezumab slightly but significantly reduced cognitive decline in subjects with mild AD; in both studies, solanezumab increased total plasma Aβ 1-40 and Aβ 1-42 levels, but decreased total CSF Aβ 1-40 and increased total Aβ 1-42 levels. Across both studies, the incidences of amyloid-related imaging abnormalities (ARIA) with edema (ARIA-E) and with hemorrhage (ARIA-H) were not substantially different between solanezumab and placebo recipients.
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A third 76-week, phase III study (EXPEDITION-3) was conducted in 2,129 patients with mild AD and biomarker evidence of Aβ brain deposition. Solanezumab did not show a statistically significant difference from placebo in the primary efficacy outcome measure (14-item Alzheimer's Disease Assessment Scale-Cognitive subscale [ADAS-Cog]), but the secondary outcomes were slightly but statistically significant in favor of the solanezumab group. Neither drug nor placebo reduced brain fibrillar amyloid on PET imaging. 5 The negative outcome of this study suggests that selection of Aβ-PET-positive patients does not necessarily improve outcomes with anti-Aβ therapy. Conversely, it could be that trials excluding Aβ-PET-negative patients are selecting subjects with more advanced disease.
Solanezumab is also being evaluated in a preventative paradigm in cognitively normal subjects at risk of AD and in subjects with familial AD mutations. A 3-year, double-blind, placebo-controlled study (A4) is evaluating solanezumab in 1,150 asymptomatic or very mildly symptomatic Aβ-PET-positive elderly subjects. The primary efficacy variable is a composite scale (ADCS-PACC) that appears sensitive to change in early cognitive decline. 3 The trial is scheduled to complete by 2022.
Another double-blind, placebo-controlled prevention study (DIAN-TU) is being conducted by the Dominantly Inherited Alzheimer Network (DIAN) in 438 asymptomatic and very mildly symptomatic carriers of autosomal-dominant mutations in APP, PSEN1, or PSEN2 genes, to test the ability of solanezumab, gantenerumab, or atabecestat to arrest or delay the onset of cognitive deficit. A first biomarker evaluation will be carried out after 2 years of treatment (DIAN-TU Biomarker trial). Drugs that look promising on AD biomarkers will advance to a 4-year study (DIAN-TU Adaptive Prevention trial) in 266 mutation carriers, the primary endpoint being a composite battery of cognitive tests (DIAN-TU cognitive composite score) sensitive to change during early disease. Doubts remain on the appropriateness of evaluating solanezumab in this study in view of the negative findings in previous large clinical studies in sporadic AD patients.
Gantenerumab
Gantenerumab (Hoffman-La Roche/Genentech) is in phase III development for the treatment of early AD. It shows higher affinities for Aβ oligomers (0.6nM) and fibrils (1.2nM) than Aβ monomers (17nM). 45 A 2-year, double-blind, placebo-controlled, phase II/III study (SCarlet RoAD) investigating gantenerumab in 797 Aβ-PET-positive prodromal AD patients was prematurely halted for failure to demonstrate efficacy, despite dose-dependent reductions in brain amyloid (PET) and CSF tau parameters being observed in the gantenerumab groups. The incidence of ARIA increased in a dosedependent and APOE ε4 genotype-dependent manner. 58 The trial was converted into an open-label extension study of the safety and biological effects of higher doses of gantenerumab using different titration schedules, depending on APOE ε4 genotype (carrier vs noncarrier) and treatment during the double-blind trial.
Another double-blind, placebo-controlled, phase II/III study (Marguerite RoAD) evaluated gantenerumab in patients with mild AD randomized to monthly doses of either placebo or gantenerumab. 59 Following interruption of the SCarlet RoAD study, this study was also halted and converted into an open-label extension trial. Two new phase III, double-blind, placebo-controlled studies (GRADUATE 1 and GRADUATE 2) started in late 2018 in patients with prodromal to mild AD and Aβ pathology (CSF or amyloid PET). The effects of gantenerumab on PET tau burden are also being evaluated. Gantenerumab is also part of the DIAN-TU, DIAN-TU Biomarker, and DIAN-TU Adaptive Prevention trials described above.
Crenezumab
Crenezumab (Genentech/Hoffman-La Roche) is in phase III development for early AD. It binds to pentameric oligomeric forms of Aβ and fibrillary 16-mer assemblies of Aβ and targets residues 13 to 16 of Aβ in different oligomeric states. 44 It also blocks aggregation and promotes disaggregation of Aβ. 60 A double-blind, placebo-controlled, phase II study (ABBY) in 433 mild-to-moderate AD patients evaluated crenezumab administered in 2 dose regimens for 68 weeks, with final evaluation at 73 weeks. The drug failed to show significant differences versus placebo on the primary endpoints (12-item ADAS-Cog and CDR-SB). 61 A smaller phase II imaging study (BLAZE) in 91 patients also failed to show cognitive or clinical benefits. No significant effects of the drug on amyloid-PET were observed, although an effect on CSF Aβ was detected. Further subgroup analyses of the ABBY and BLAZE studies suggested a possible efficacy signal in milder AD patients, but these were based on very limited sample sizes and were not corrected statistically for multiple comparisons.
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A further double-blind, placebo-controlled phase Ib study in 75 Aβ-PET-positive subjects with mild-tomoderate AD evaluated higher intravenous doses of crenezumab (30, 45, 60, 120 mg/kg/4 weeks for 13 weeks). There were 9 serious adverse events and 2 cases of brain microhemorrhage (ARIA-H).
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A 100-week, double-blind, placebo-controlled phase III study in 750 Aβ-PET-positive patients with prodromal to mild AD (CREAD) is evaluating crenezumab using change in CDR-SB score at 2 years as the primary efficacy endpoint. Substudies will explore effects on CSF biomarkers and amyloid-PET. Magnetic resonance imaging (MRI) examinations will assess safety and volumetric changes. 64 The study should be completed in September 2020. A matching study in 750 subjects with prodromal to mild AD (CREAD2) is also underway, using the same dose as the CREAD study. This will be completed in November 2021. Crenezumab is also being tested as a preventive treatment in a double-blind, placebo-controlled study in 252 presymptomatic carriers of autosomal-dominant presenilin mutation (PSEN1 E280A). Bimonthly, subcutaneous injections of crenezumab or placebo will continue for 5 years. 65 The primary efficacy outcome is the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Composite Cognitive Test; the study is scheduled to be completed by March 2022.
Aducanumab Aducanumab (Neurimmune/Biogen) is in development for the treatment of prodromal AD. It binds to soluble Aβ aggregates and insoluble fibrils with >10,000-fold selectivity over monomers. 66 A phase Ib, 12-month, double-blind, placebo-controlled, multiple ascending study evaluated intravenous doses from 1 to 10 mg/kg every 4 weeks in 165 Aβ-PET-positive prodromal and mild AD patients. 67 Of the 165 dosed patients, 40 discontinued treatment (24%), most due to adverse events (20 patients) and withdrawal of consent (14 patients). Adverse event discontinuations occurred in 10%, 10%, 6%, 10%, and 31% in the placebo and 1-, 3-, 6-, and 10 mg/kg groups, respectively. ARIA-E events occurred in no patients receiving placebo compared with 3%, 6%, 37%, and 41% of patients receiving 1, 3, 6, and 10 mg/kg aducanumab, respectively. Aducanumab dosedependently and time-dependently decreased brain amyloid burden at 52 weeks and reduced decline in both MMSE and the CDR-SB scores compared to placebo. The effect of the 10 mg/kg dose reached statistical significance on both variables, although no adjustments were made for multiple comparisons. These encouraging data represent the first time that a lowering effect on Aβ brain load has been coupled with a positive effect on cognition and clinical status with dosedependent trends. However, a potential interpretation bias lies in the clinical stage of the dropouts. The majority of dropouts in the 10 mg/kg group (52.6%) were patients with mild AD at baseline, whereas there was only 1 dropout among prodromal AD patients at that dose (7.7%). Conversely, in the placebo groups there were similar discontinuation rates among mild and prodromal AD patients (28.6% vs 21.1%). The criteria for definition of prodromal AD were an MMSE of 24 to 30 (inclusive) and a CDR of 0.5, whereas for mild AD they were an MMSE of 20 to 26 and a CDR of 0.5 to 1. Thus, the imbalance in the proportion of prodromal AD and mild AD dropouts in the 10 mg/kg group may have contributed to the apparently slower decline observed. One possible explanation could be a higher incidence of ARIA-E abnormalities in the mild AD group. Compared to prodromal AD, mild AD patients may have higher Aβ burden in brain vessels and consequently a greater risk of edema or bleeding due to Aβ removal by aducanumab. After the completion of this study, a further arm of 31 APOE ε4 carriers was added. In this group, ARIA-E occurrence was 35%. About 80% of patients completing these doubleblind phases entered a long-term open extension period, with everyone receiving aducanumab. At 24 months, mean changes in brain Aβ load (standardized uptake value ratio) and worsening in MMSE compared to baseline showed indications of benefit associated with the change in dose received during the open-label treatment.
Two phase III, 18-month trials of aducanumab, ENGAGE (NCT02477800) and EMERGE (NCT024845 47), are currently enrolling Aβ-PET-positive patients with early AD (CDR global score of 0.5 and MMSE score of [24] [25] [26] [27] [28] [29] [30] . 68 An 18-month, phase IIb study in 856 subjects with prodromal or mild AD evaluated 5 dose regimens (2.5 mg/kg every 2 weeks, 5 mg/kg once monthly, 5 mg/kg biweekly, 10 mg/kg monthly, 10 mg/kg biweekly) versus placebo. 70 A Bayesian adaptive design approach was used to randomize subjects into treatment arms with a higher likelihood of efficacy after interim data evaluation. At 18 months, the reduction of accumulated amyloid brain plaques on PET was statistically significant at all doses. At the highest dose of 10 mg/kg biweekly there was a mean Centiloid scale reduction from 74.5 at baseline to 5.5. There was also a dose-dependent slowing in cognitive decline from baseline on the ADCOMS. At 10 mg/kg biweekly, the reduction was 30% versus placebo (p = 0.034). This dose also slowed cognitive decline on the ADAS-Cog by 47% compared to placebo (p = 0.017). However, the slowing in cognitive decline on the CDR-SB was not statistically significant. Dosedependent increases in Aβ levels were observed in CSF (p < 0.0001 at the highest dose at 18 months), and there was a statistically significant reduction in total tau levels versus placebo in both 10 mg/kg dose regimens (p < 0.05). The treatment-related adverse event rates were 26.5% (placebo), 53.4% (10 mg/kg monthly), and 47.2% (10 mg/kg biweekly). ARIA-E did not occur in >10% of patients in any of the treatment arms but was 14.6% among APOE ε4 carriers in the 10 mg/kg biweekly group. Concerns about ARIA led regulators to limit the number of APOE ε4 carriers in the high-dose group to 30%, a percentage substantially lower than in the placebo and other dose groups (from 70 to 91%). This unbalance may have impacted the rates of cognitive decline between the various arms and contributed to the appearance of benefit of the 10 mg/kg biweekly group compared to placebo.
Criticism of the Amyloid Cascade Hypothesis
The amyloid cascade hypothesis is strongly supported by data from rare autosomal-dominant forms of AD, but the evidence for sporadic AD is less clear. Unresolved issues with the hypothesis include the presence of Aβ deposition in cognitively normal individuals; the weak correlation between Aβ plaques and clinical severity; the nature, presence, and role of Aβ oligomers in humans; and the poorly explained pathological heterogeneity and comorbidities associated with AD. [71] [72] [73] Aβ pathology as the source of neurodegeneration through tau has been the core of the amyloid hypothesis. However, in autopsy studies, tau pathology has been observed before marked Aβ deposition even in young subjects. 74 The discovery of subjects with neurodegeneration biomarkers (low hippocampal volume and low glucose metabolism) but no Aβ deposits (suspected non-AD pathology [SNAP]) 75 suggests they could either be in the earliest stage of AD or possibly have a different disease. The annual conversion rates to mild cognitive impairment for cognitively normal elderly subjects with SNAP and subjects with Aβ amyloidosis are almost identical (10% vs 11%), 76 and individuals with SNAP are indistinguishable on any clinical risk factors, indicating that the appearance of brain injury biomarkers in cognitively normal persons may not depend on Aβ amyloidosis. 75 Neuronal injury independent of Aβ deposition also occurs in APOE ε4 carriers, 77, 78 and studies in APP or PSEN mutation carriers have revealed that neuronal injury is evident before or at the same time as Aβ deposition. 78 These findings question the sequential biomarker model of AD and the amyloid cascade hypothesis 79 and suggest that AD is a multiparameter pathology in which tau promotes Aβ toxicity. Cognitively healthy Aβ-positive individuals thus represent a substantial challenge to the hypothesis. Although longitudinal studies show that such subjects may be at risk for future cognitive impairment, that impairment may be minor and clinically irrelevant. 18, 19, 80 Even if brain amyloid deposition in these subjects does parallel cognitive decline over time, it may still be secondary to other processes. 81 Because
Aβ deposition starts with progressive aggregation of soluble oligomers, it seems likely that these individuals have been exposed to Aβ oligomers (and any neurotoxic effects) for a long time. Therefore, the absence of overt dementia again undermines the hypothesis. 82 A common criticism of drug discovery in AD is the identification of potential drugs using data from human APP or PSEN transgenic mouse models and their subsequent clinical testing in sporadic AD. It is good that academic groups like API and DIAN are promoting trials in subjects with APP or PSEN mutations of drugs selected using corresponding transgenic mice. If these studies are negative, we should probably conclude that the Aβ hypothesis of AD is invalid for both genetic and sporadic formsif positive, we may conclude that the mechanisms of the two forms have some critical differences.
Physiological Role of Aβ
Aβ is widely distributed through the body in AD patients and healthy individuals; there is evidence that soluble Aβ serves a variety of physiological functions in regulating neuronal electrophysiology, 83 synaptic plasticity and memory, 84 long-term potentiation, 85 neuronal transmission, 86 learning and memory, 87 hippocampal and memory consolidation, 84 neurogenesis, 88 and neuronal survival. 89, 90 Interestingly, brain Aβ may be increased in numerous neurologic conditions other than AD: traumatic brain injury, 91 chronic traumatic encephalopathy, 92 general anesthesia, 93 amyotrophic lateral sclerosis, 94, 95 major depressive disorder, 96 cerebral ischemia, 97 and multiple sclerosis. 98 Patients undergoing cardiac surgery or suffering cardiac arrest also show rapid changes in Aβ levels in CSF/plasma, 99, 100 even infants and children, 101 probably from a combination of mechanical trauma and anesthetic insult. An increase in CSF Aβ levels is also observed in cognitively normal adults after 1 day of sleep deprivation 102 or slow-wave sleep disruption. 103 Interestingly, the increase in brain Aβ levels after chronic sleep restriction in normal adult mice is due to an upregulation of BACE pathway. 104 The mechanism for such increased Aβ production is unclear and may be disease-specific, but may well be a response to neuronal damage or insult. Similarly, in AD, Aβ overproduction and accumulation may represent a chronic attempt to protect neuronal functioning. 105 The real cause of the initial neuronal damage would not be Aβ accumulation but other possible insults like chronic inflammation, 106 82 Thus, Aβ production in AD could represent an adaptive response to an upstream pathophysiological process. In the absence of a reparative neuronal outcome, prolonged overproduction leads to aggregation, with activation of the well-known deleterious cascade.
Conclusions
The Aβ hypothesis of AD was formulated 25 years ago on the basis of strong genetic, biochemical, and histopathological evidence, subsequently strengthened by further genetic, longitudinal biomarker, and clinical studies. However, >15 years of failure with several classes of drugs targeting Aβ have started to raise questions, 1 particularly their apparent tendency to accelerate cognitive decline compared to placebo. The recent discovery of the diverse physiological roles of Aβ makes it highly possible that during prodromal AD unidentified neurotoxic influences may be responsible for a compensatory increase in Aβ levels, leading to the cascade of biological and clinical events elucidated in recent years. This alternative hypothesis could explain the disappointing results seen with anti-Aβ therapy. However, any challenge to the amyloid hypothesis must offer an explanation for the role of APP and PSEN gene mutations in autosomal-dominant familial AD, and the AD scientific community should strive to address this. A "stress threshold change of state" model of AD has recently been proposed and may explain the existence of both early onset familial AD and late onset sporadic AD forms of the disease. 81 The results of ongoing studies with anti-Aβ drugs in preclinical to asymptomatic stages of AD, or in cognitively normal subjects at risk for AD, will hopefully resolve this debate. In the meantime, it is imperative that alternative hypotheses are considered and actively pursued.
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